Comparative Pharmacology
Head-to-head clinical analysis: LACTULOSE versus XPHOZAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LACTULOSE versus XPHOZAH.
LACTULOSE vs XPHOZAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a non-absorbable disaccharide that is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, resulting in an osmotic effect that increases stool water content and softens stools. In hepatic encephalopathy, lactulose acidifies the colonic lumen, converting NH3 to NH4+, which is poorly absorbed, and reduces systemic ammonia levels.
XPHOZAH (tenapanor) is a sodium-hydrogen exchanger 3 (NHE3) inhibitor. It acts locally in the gastrointestinal tract to inhibit NHE3, reducing sodium and phosphate absorption, leading to decreased serum phosphate levels.
Constipation: 15-30 mL (10-20 g) orally once daily, increased to 45-60 mL (30-40 g) daily if needed. Hepatic encephalopathy: 30-45 mL (20-30 g) orally 3-4 times daily; titrate to produce 2-3 soft stools daily.
10 mg orally three times daily (TID) with or without food.
None Documented
None Documented
Clinical Note
moderateL-Glutamine + Lactulose
"The therapeutic efficacy of Lactulose can be decreased when used in combination with L-Glutamine."
1-2 hours (terminal elimination half-life for lactulose). However, its clinical effect is not dependent on systemic half-life; the drug acts locally in the colon.
Terminal elimination half-life is approximately 14 days, supporting monthly subcutaneous dosing for sustained serum phosphate reduction.
Primarily fecal (unaltered, >90%). Minimal renal excretion (<5% as metabolites). Very small amount (approximately 3%) excreted in urine as unchanged drug.
Primarily eliminated in feces (approximately 92%) as unchanged drug; renal excretion is negligible (<1%).
Category C
Category C
Laxative
Laxative